NCT05117125

Biomarkers for Ventilator-associated Pneumonia

Biomarkers for Prediction of and Diagnosis of Ventilator-associated Pneumonia

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 1,000 (estimated)
• Sponsor: Region Skane · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate different peptide biomarkers, variations in the microbiome and patterns in the bacterial transcriptome as prognostic or diagnostic biomarkers of VAP.

Conditions

• Pneumonia, Ventilator-Associated

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	Heparin-binding protein	Evaluation of the specificity and sensitivity of HBP as diagnostic biomarker for VAP.
DIAGNOSTIC_TEST	Interleukin-26	Evaluation of the specificity and sensitivity of IL-26 as diagnostic biomarker for VAP.
DIAGNOSTIC_TEST	Microbiome	Evaluation of the specificity and sensitivity of the lung microbiome as prognostic biomarker for VAP.
DIAGNOSTIC_TEST	Bacterial transcriptome	Evaluation of the specificity and sensitivity of the bacterial transcriptome as prognostic biomarker for treatment failure of VAP.
DIAGNOSTIC_TEST	Proteome	Evaluation of the specificity and sensitivity of the proteome in mini-BAL as biomarker for VAP.

Timeline

• Start date: 2021-10-15
• Primary completion: 2026-12-31
• Completion: 2028-12-31
• First posted: 2021-11-11
• Last updated: 2024-11-15

Locations

5 sites across 3 countries: Norway, Portugal, Sweden